Kezdőlap・Részvénylista・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Nyitva

14.72 0.89

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

14.39

Maximum

14.74

Fő mutatók
By Trading Economics
Bevétel	-4.3M -18M
Egy részvényre jutó nyereség	-0.19
Munkavállalók	37
EBITDA	-5.3M -17M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+102.61% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. nov. 3.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	61M 1.2B
Előző nyitás	13.83
Előző zárás	14.72

Corvus Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 25. 23:56 UTC

Correlated Moves

Emerson Electric Co's shares are lower in after-market hours, reflecting a decline since Tuesday's close amid broader market sentiment influencing the stock's movement.

2026. aug. 25. 23:56 UTC

Charles River Laboratories shares are higher in after-market trading, maintaining a position near the upper end of their one-month range amid lower crude oil prices.

2026. aug. 25. 23:56 UTC

Host Hotels and Resorts, Inc. shares are lower in after-market hours. No specific news was identified to explain the decline, amid falling crude oil prices.

2026. aug. 25. 23:56 UTC

Correlated Moves

KKR & Co Inc shares are lower in after-market hours, reflecting broader trends in the financial sector amid minimal change since Tuesday's close.

2026. aug. 25. 23:56 UTC

ETF Constituents

Correlated Moves

Vanguard Morningstar Mid-Cap ETF trades higher after-market, supported by contributions from HWM, PWR, VST, NET, and LHX amid a rising Russell 2000 Index.

2026. aug. 25. 23:56 UTC

Correlated Moves

M&T Bank Corp shares are lower in after-market trading, influenced by a decline in Wells Fargo and broader market sentiment affecting the banking sector.

2026. aug. 25. 23:56 UTC

Allogene Therapeutics Inc. is trading roughly flat in after-market hours, maintaining a position near the upper end of its one-month range.

2026. aug. 25. 23:56 UTC

Correlated Moves

NiSource Inc shares are trading lower in after-market hours, influenced by a decline in Sempra and broader market sentiments affecting utility stocks.

2026. aug. 25. 23:56 UTC

Toast Inc shares are higher in after-market trading, maintaining a position above the 20-day moving average and near the upper end of their one-month range.

2026. aug. 25. 23:56 UTC

Baker Hughes Co's shares are higher in after-market trading, with no specific news identified. Broader market trends may be influencing positive sentiment.

2026. aug. 25. 23:56 UTC

Correlated Moves

Johnson Controls International PLC shares rose in after-market trading, reflecting modest gains amid favorable investor sentiment and a correlation with nVent Electric PLC.

2026. aug. 25. 23:56 UTC

Correlated Moves

Public Service Enterprise Group Inc. sees modest gains in after-market trading, aligning with broader trends from related companies like DTE Energy Co.

2026. aug. 25. 23:56 UTC

Correlated Moves

Shares of APA Corp declined in after-market trading, continuing a trend of lower daily finishes, amid falling WTI crude oil prices.

2026. aug. 25. 23:56 UTC

Fidelity National Information Services shares are trading lower in after-market hours. The asset remains below its 20-day moving average.

2026. aug. 25. 23:56 UTC

Williams Companies Inc. shares are higher in after-market trading, reflecting a slight gain since Tuesday's close amid declining crude oil prices and lower treasury yields.

2026. aug. 25. 23:56 UTC

Diamondback Energy shares traded roughly flat in after-market hours, following four consecutive sessions of declines amid lower crude oil prices and treasury yields.

2026. aug. 25. 23:56 UTC

Correlated Moves

Fifth Third Bancorp remains roughly flat in after-market trading, despite a slight increase in the Dow Jones Index and declining crude oil prices.

2026. aug. 25. 23:56 UTC

Correlated Moves

Jones Lang LaSalle Inc shares are lower in after-market trading, reflecting a broader decline in the real estate sector alongside Marcus & Millichap Inc.

2026. aug. 25. 23:52 UTC

Mexico's Business Confidence Remains Low at 48.0 Ahead of Key Survey Amid Mixed Trade Sentiments with the U.S.

2026. aug. 25. 23:52 UTC

Brazil's Q2 2026 GDP Growth Rate Release Looms Amid Declining Consumer Confidence and Cautious Market Sentiment.

2026. aug. 25. 23:52 UTC

Brazil's Q2 2026 GDP growth release on September 1 expected to reflect strong government spending amid mixed consumer confidence and rising inflation concerns.

2026. aug. 25. 23:52 UTC

India's Current Account Balance Release on September 1, 2026 Expected to Impact Market Sentiment Amid Rising Import Costs and Geopolitical Pressures.

2026. aug. 25. 23:52 UTC

Brazil's Central Bank to Announce SELIC Rate Decision Amid Global Monetary Policy Uncertainty on August 31, 2026.

2026. aug. 25. 23:52 UTC

Social Media

Warner Bros Discovery Inc shares traded lower in after-market hours amid ongoing scrutiny in the antitrust case involving Paramount and related legal developments.

2026. aug. 25. 23:52 UTC

UniFirst Corp shares declined in after-market trading, despite a favorable macro environment with falling crude oil prices and lower Treasury yields.

2026. aug. 25. 23:51 UTC

DraftKings shares are higher in after-market trading amid favorable market conditions and a decline in crude oil prices. No specific news was identified.

2026. aug. 25. 23:51 UTC

Travel + Leisure Co shares are higher in after-market hours. No specific company news was identified, but declining crude oil prices may be influencing sentiment.

2026. aug. 25. 23:51 UTC

Correlated Moves

American Water Works shares are higher in after-market trading, supported by a decline in crude oil prices and easing inflation concerns.

2026. aug. 25. 23:51 UTC

Asia equity markets mixed as investors react to geopolitical tensions, falling crude oil prices, and await key U.S. economic data releases.

2026. aug. 25. 23:51 UTC

Mixed trading in Europe as Germany's Ifo index rises, while France's consumer confidence dips; U.S. markets gain on falling oil prices and tech stock rallies ahead of key earnings.

Társak összehasonlítása

Árváltozás

Corvus Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

102.61% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 29.5 USD 102.61%

Magas 33 USD

Alacsony 27 USD

4 Wall Street elemző 12 hónapos célárain alapulva a(z)Corvus Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

4 ratings

Vétel

Tartás

Eladás

4 Wall Street elemző célárain alapulva a(z)Corvus Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.